These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6135423)

  • 1. Inhibition of platelet thromboxane synthetase by sulfasalazine.
    Stenson WF; Lobos E
    Biochem Pharmacol; 1983 Jul; 32(14):2205-9. PubMed ID: 6135423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
    Tornhamre S; Edenius C; Smedegård G; Sjöquist B; Lindgren JA
    Eur J Pharmacol; 1989 Oct; 169(2-3):225-34. PubMed ID: 2572437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of human colonic arachidonic acid metabolism by sulfasalazine.
    Hawkey CJ; Boughton-Smith NK; Whittle BJ
    Dig Dis Sci; 1985 Dec; 30(12):1161-5. PubMed ID: 2866075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
    Oketani K; Nagakura N; Harada K; Inoue T
    Eur J Pharmacol; 2001 Jun; 422(1-3):209-16. PubMed ID: 11430933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of effects of sulfasalazine and its metabolites on the metabolism of endogenous vs. exogenous arachidonic acid.
    Allgayer H; Stenson WF
    Immunopharmacology; 1988; 15(1):39-46. PubMed ID: 2896181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.
    Stenson WF; Lobos E
    J Clin Invest; 1982 Feb; 69(2):494-7. PubMed ID: 6120182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet thromboxane synthetase by L-1-tosylamido-2-phenylethyl chloromethyl ketone.
    Yahn DM; Feinstein MB
    Prostaglandins; 1981 Feb; 21(2):243-54. PubMed ID: 7194491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
    Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
    Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.
    Nielsen OH; Bukhave K; Elmgreen J; Ahnfelt-Rønne I
    Dig Dis Sci; 1987 Jun; 32(6):577-82. PubMed ID: 2882965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone(AHR-5333): a selective human blood neutrophil 5-lipoxygenase inhibitor.
    Graff G; Anderson LA
    Prostaglandins; 1989 Oct; 38(4):473-96. PubMed ID: 2554366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
    Tateson JE; Randall RW; Reynolds CH; Jackson WP; Bhattacherjee P; Salmon JA; Garland LG
    Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.
    Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Murakami M; Oketani K; Inoue T
    J Med Chem; 1994 Sep; 37(19):3062-70. PubMed ID: 7932529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfasalazine and its anti-inflammatory metabolite, 5-aminosalicylic acid: effect on arachidonic acid metabolism in human neutrophils, and free radical scavenging.
    Ahnfelt-Rønne I; Nielsen OH; Bukhave K; Elmgreen J
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17B():918-22. PubMed ID: 2890286
    [No Abstract]   [Full Text] [Related]  

  • 15. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
    Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
    Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of prostaglandin synthetase in human rectal mucosa.
    Hawkey CJ; Lo Casto M
    Gut; 1983 Mar; 24(3):213-7. PubMed ID: 6131017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of arachidonic acid metabolism by olsalazine and other aminosalicylates in leukocytes.
    Horn H; Preclik G; Stange EF; Ditschuneit H
    Scand J Gastroenterol; 1991 Aug; 26(8):867-79. PubMed ID: 1685260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets.
    Uotila P; Matintalo M
    Prostaglandins Leukot Med; 1984 Apr; 14(1):41-6. PubMed ID: 6427791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of E3040, an inhibitor of 5-lipoxygenase and thromboxane synthase, on rat bowel damage induced by lipopolysaccharide.
    Oketani K; Inoue T; Murakami M
    Eur J Pharmacol; 2001 Sep; 427(2):159-66. PubMed ID: 11557269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of arachidonic acid lipoxygenase products during platelet-neutrophil interactions.
    Marcus AJ; Broekman MJ; Safier LB; Ullman HL; Islam N; Serhan CN; Weissmann G
    Clin Physiol Biochem; 1984; 2(2-3):78-83. PubMed ID: 6435929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.